{"preliminary_commentary":{"by_channel":{"podcast":7,"youtube":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06790693\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"INAVO 123","nct_id":"NCT06790693","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=inavo-123-nct06790693. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"INAVO123","arms":[{"description":"Participants will receive inavolisib, letrozole and CDK4/6i.","label":"Inavolisib + Letrozole + CDK4/6i","type":"EXPERIMENTAL"},{"description":"Participants will receive placebo, letrozole and CDK4/6i.","label":"Placebo + Letrozole + CDK4/6i","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2032-02-01","type":"ESTIMATED"},"conditions":["Breast Cancer"],"enrollment":{"count":450,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Inavolisib","otherNames":["GDC-0077","Itovebi"],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"},{"name":"CDK4/6i","otherNames":[],"type":"DRUG"},{"name":"Letrozole","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-06","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2032-01-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS)","timeFrame":"From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 7 years)"}],"references":[],"start_date":{"date":"2025-04-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer","url":"https://clinicaltrials.gov/study/NCT06790693"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/inavo-123-nct06790693"}